Adjuvant chemotherapy of breast cancer
|
|
- Julian Hoover
- 5 years ago
- Views:
Transcription
1 Journal of BUON 10: , Zerbinis Medical Publications. Printed in Greece REVIEW ARTICLE Adjuvant chemotherapy of breast cancer S. Bešlija Department of Medical Oncology, Institute of Oncology, Clinical Center of Sarajevo University, Sarajevo, Bosnia and Herzegovina Summary Breast cancer is the most common cancer and the second most common cause of cancer-related death in women. The last three decades have yielded marked progress in the diagnosis and management of breast cancer. Not only is the disease being detected at a much earlier stage, but the addition of systemic therapy has also improved survival. Cyclophosphamide (C), methotrexate (M) and 5-fluorouracil (F) (CMF) combination chemotherapy was among the first chemotherapy regimens found to prolong both disease-free survival (DFS) and overall survival (OS) when given in the adjuvant setting. The 2000 Oxford overview confirmed that anthracycline-based chemotherapy offers a survival advantage compared with CMF. Anthracycline-based therapies are better tolerated in terms of acute side effects but longterm sequels (cardiotoxicity, secondary leukaemia) are worrisome. It seems that more intensive three-drug regimens (FE[epirubicin] 100 C, CEF, CA[adriamycin]F,) or the combination of E+CMF are more active in reducing the risk of relapse and death in breast cancer patients. The reported trials with taxanes demonstrated comparable reduction in the risk of recurrence and death, although administration of paclitaxel (T)-containing regimens appears to be most effective if administered on an every-2-week schedule with granulocyte colony-stimulating factor (G-CSF). The risk of febrile neutropenia is highest for the TAC regimen (~25%), although other trials have demonstrated that use of G-CSF will reduce this complication to about 3%. Key words: adjuvant, breast, cancer, chemotherapy Received ; Accepted Author and address for correspondence: Semir Bešlija, MD Department of Medical Oncology Institute of Oncology Clinical Center of Sarajevo University Bolnicka Sarajevo Bosnia and Herzegovina Tel/Fax: sbeslija@onkokcus.bih.net.ba Breast cancer is the most common cancer and the second most common cause of cancer-related death in women. The last three decades have yielded marked progress in the diagnosis and management of breast cancer. Not only is the disease being detected at a much earlier stage, but the addition of systemic therapy has also improved survival [1]. At diagnosis, many women with primary breast cancer already have distant micrometastases. With time, most of these women will progress to overt metastatic disease, even after surgery and radiotherapy. Systemic adjuvant therapy for early-stage breast cancer is thus used to prevent or delay disease progression and offers the prospect of cure by eliminating micrometastases. CMF combination chemotherapy was among the first chemotherapy regimens found to prolong both DFS and OS when given in the adjuvant setting [2,3]. CMF given beyond 6 months did not reduce mortality or relapse rate, and there was little difference in the results between patients receiving CMF of 3 to 6-month duration. The many versions of CMF therapy, including those entailing oral or intravenous drug administration, appear generally equal, but it is quite possible that oral CMF could be superior, as suggested in studies of metastatic disease [4,5]. The 2000 Oxford overview [6] confirms the 1995 data that anthracycline(a)-based chemotherapy offers a survival advantage compared with CMF. A-based therapies are better tolerated in terms of acute side
2 176 effects [7], but long-term sequels (cardiotoxicity, secondary leukaemia) are worrisome [8,9]. To evaluate which A-based treatment is the best for use in standard clinical practice, the better approach could be an analysis of one-to-one comparison between A-based regimens and CMF. It seems that the more intensive three-drug A-based regimens (FE 100 C, CEF, CAF) [10-12] or the combination of E+CMF [13] are more active in reducing the risk of relapse and death in breast cancer patients than CMF. Nevertheless, CMF remains a valid option for selected groups of patients (elderly, cardiac dysfunction, node-negative, hormone receptor-positive, HER2-negative). Dose-escalating regimens have been used to increase efficacy and prevent resistance to some chemotherapeutic agents. NSABP 22 and 25 trials indicate that cyclophosphamide doses > 600 mg/m 2 do not improve DFS or OS but do significantly increase toxicity [14,15]. Doses of doxorubicin > 60 mg/m 2 have shown no clear benefit and are not recommended outside of clinical trials [16]. Epirubicin has structural differences compared with doxorubicin and consequently different safety profile. Larger doses of epirubicin are required to produce the same degree of toxicity as doxorubicin. Dose-dense treatment emphasizes manipulation of dose schedule by decreasing the time interval between cycles rather than dose level. The Cancer and Leukemia Group B (CALGB) clinical study 9741 (Intergroup C9741) [17] posed two questions: is combination chemotherapy superior to a sequence of single agents, and is dose density important? The first question was addressed by comparing the standard doxorubicin and cyclophosphamide combination (AC) followed by paclitaxel against the sequential administration of doxorubicin, then paclitaxel, then cyclophosphamide. All patients received 4 courses of these 3 agents (doxorubicin 60 mg/m 2, cyclophosphamide 600 mg/m 2, and paclitaxel 175 mg/m 2 ). The comparison revealed no significant differences between the 2 protocols. To determine the impact of dose density, the same patients were also randomized to receive their chemotherapy using 2- or 3-week intervals. The 2-week interval required growth factor support (filgrastim), whereas filgrastim was administered as needed in the every-third-week arm. Treatment using the 2-week interval was associated with improved DFS and OS, reduced rate of neutropenic fever (no doubt attributable to the growth factor support), and was of course one third shorter. Hence, a shorter, safer treatment was associated with improved disease-specific outcomes. This study was recently published [18] and a protocol-specified analysis was performed at a median follow-up of 36 months: 315 patients had experienced relapse or died, compared with 515 expected treatment failures. Dose-dense treatment improved the primary endpoint, DFS (risk ratio [RR] = 0.74; p=0.010), and OS (RR = 0.69; p=0.013). Four-year DFS was 82% for the dose-dense regimens and 75% for the others. There was no difference in either DFS or OS between the concurrent and sequential schedules. There was no interaction between density and sequence. Severe neutropenia was less frequent in patients who received the dosedense regimens with the conclusion that dose density improves clinical outcomes significantly, despite the lower than expected number of events at this time. Sequential chemotherapy was as effective as concurrent chemotherapy. This trial was correctly designed and performed but there is still a number of questions to be answered: we will have to wait for the data regarding long-term efficacy and toxicity; the trial did not have enough power to make an individual comparison between the 4 arms and is missing prospective stratification for estrogen receptor (ER) status. Finally, lacking are data regarding quality of life as well as cost/benefit ratio. The use of high-dose chemotherapy is based on the hypothesis that high doses will overcome drug resistance, eradicate metastatic disease, and increase the proportion of women who are cured. According to the results from several randomized clinical studes [19-22], high-dose therapy cannot be considered standard for adjuvant therapy in any known group of women with high risk of relapse and has to be offered to the patients only in a clinical trial setting. Further studies and longer follow-up are awaited before any recommendations regarding the role of high-dose therapy can be established. In recent years, the taxanes have been investigated in several trials of adjuvant therapy of women with node-positive breast cancer. The two major trials in which paclitaxel was used (NSABP B28 and CALGB- 9344) provided evidence about the role of taxanes in adjuvant therapy [23,24]. In the CALGB 9344 trial, patients with node-positive disease were randomized to receive either 4 cycles of doxorubicin and cyclophosphamide (AC) or the same regimen followed by 4 cycles of paclitaxel. The patients were randomized in 3 dose levels of doxorubicin. The majority of the enrolled patients (94%) had ER-positive tumors and received tamoxifen following completion of chemotherapy. While the dose of doxorubicin did not have an impact on outcome, in the published article at a median follow-up of 69 months [25] the group of patients treated with paclitaxel have had significantly
3 177 greater 5-year DFS (70 versus 65%; p=0.0023) and OS (80 versus 77%; p=0.0064). The addition of paclitaxel yielded a statistically significant reduction in the risk of reccurence and death of 17% and 18%, respectively. An unplanned subgroup analysis showed that the paclitaxel arm was more affecting the reduction of the risk of relapse in patients with ER-negative tumors. The additional toxicity deriving from the sequential use of paclitaxel was generally modest. In the NSABP B28 trial [24], 3059 patients with node-positive disease were randomized to receive 4 cycles of doxorubicin and cyclophosphamide (AC), or the same regimen followed by 4 cycles of paclitaxel at a dose of 225 mg/m 2. Tamoxifen was administered to all patients aged > 50 years, as well as to younger women with ER-positive disease. The patients of this study represented a better risk group compared with the CALGB study in terms of number of positive nodes and hormone receptor positivity. The initial analysis of the NSABP B28 trial showed no difference in outcome between patients treated with AC alone and those treated with AC and paclitaxel [25]. A more recent update at a median follow-up of 64 months showed that patients receiving paclitaxel had a statistically significant reduction in the risk of relapse but they did not have statistically significant reduction in the risk of death [26]. The absolute benefit of adding paclitaxel in the adjuvant treatment of breast cancer remains uncertain, mainly due to the control regimen used in both trials which seems to be suboptimal. Patients in the control arms in both of these trials received only 4 cycles of treatment compared with 8 received in the experimental arm. Four cycles of AC have been shown to be equivalent to, but not more effective than 6 cycles of CMF, as mentioned above. Three-drug anthracyclinecontaining combinations administered for 6 or more cycles have been shown to be superior to 6 cycles of CMF [10-12]. The first large trial that evaluated the use of docetaxel in the adjuvant setting was reported by Nabholtz et al. (Breast Cancer International Research Group - BCIRG 001) [27]. They compared 6 cycles of standard 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy (500, 50, and 500 mg/m 2, respectively, every 3 weeks) versus docetaxel, doxorubicin, and cyclophosphamide (TAC) (75, 50, and 500 mg/m 2, respectively, every 3 weeks). This study provided evidence that docetaxel may have an important role when used as a component of adjuvant therapy for patients with high-risk operable or locally advanced breast cancer. There were 3 important points that might limit the application of the TAC regimen. First, the febrile neutropenia rate was very high (24%), suggesting that patients may need to be selected carefully for this regimen. Second, surprisingly TAC was found not to be beneficial in patients at highest risk (>3 positive nodes), a group in which clinicians would most likely accept a higher toxicity rate if the treatment was more effective. Finally, the trial did not include patients older than 70 years. On the other hand, there was clear benefit when this docetaxel-based regimen was used in patients with ER and/or PR-positive disease, which was not the case when paclitaxel was used sequentially following doxorubicin-cyclophosphamide in such patients. All these considered, however, this study suggests that TAC may be a reasonable alternative for the group that demonstrated clear benefit: relatively young women with 1-3 positive axillary nodes, irrespective of hormone receptor status. On the latest San Antonio Breast Cancer Meeting, Mackey and colleagues from the BCIRG reported an update of the BCIRG 001 trial [28]. This report represents an update with 55 months median follow-up at a second interim analysis preplanned to occur after 400 events, compared with 33 months at the first interim analysis performed after about 300 recurrences; in the current analysis, 92% of patients have been followed for at least 4 years. The results were compared with those of the first interim analysis (Table 1). In the first analysis, TAC was associated with a significant reduction in the risk of recurrence but not death (p=0.11, log rank test), although the risk of death was significantly reduced in a preplanned Cox proportional hazard model adjusted for baseline prognostic factors. In the updated analysis, TAC was now associated with a significant reduction in the risk of both recurrence and death (log rank test). In a Cox analysis adjusted for prognostic factors, TAC was again associated with a significant improvement in DFS (hazard ratio for recurrence 0.72; p=0.0010) and OS (hazard ratio for death 0.70; p=0.008), a finding that is nearly identical to that of the initial report. Also similar to the original report, subgroup analysis revealed benefit for the TAC arm in patients with 1-3 positive axillary nodes, hormone receptor-positive or negative disease, and HER2/neu-positive or negative disease, but not in patients with 4 or more positive axillary nodes; the latter group comprised 568 patients, and the lack of benefit for this group remains somewhat surprising. However, the study is not powered to address the difference in the 4+ node subgroup until the final analysis is planned after 580 events. This report confirms that TAC chemotherapy may be a reasonable treatment option for patients with operable node-positive breast cancer. The results reported for BCIRG 001 are contrasted with results from
4 178 Table 1. Comparison of first and second interim analyses BCIRG 001 [17,18] Initial report Current report Planned interim analysis First Second Median follow-up period (months) No. of recurrences No. of deaths Hazard rate - recurrence* 0.68 (p=0.0002) 0.72 (p=0.0010) Hazard rate death* 0.71 (p=0.049) 0.70 (p=0.008) *Cox proportional hazard model (adjusted for nodal status) of the preclinically proven activity with some drugs which are not so active in breast cancer (platinum), duration of therapy and the future role of the every 3 weeks administration. Additionally, analysis of retrospective data suggests that HER2 overexpressing tumors may be particularly sensitive to anthracyclines and anthracycline dose intensity, and less responsive to CMF. There is no doubt that HER2 overexpressing tumors are associated with a worse prognosis and more aggressive course but the predictive value of this receptor still has to be answered. 3 other phase III trials that have evaluated taxane-containing therapy for node-positive breast cancer (Table 2). All trials demonstrate comparable reduction in the risk of recurrence and death, although administration of the paclitaxel-containing regimens appears to be most effective if administered on an every 2-week schedule with G-CSF. The risk of febrile neutropenia is highest for the TAC regimen (~25%), although other trials have demonstrated that use of G-CSF will reduce this complication to about 3%. Finally, there are about women who are enrolled in clinical trials, which will give us the answers regarding the optimal use of taxanes in the adjuvant setting. The successful introduction of trastuzumab, a recombinant humanized monoclonal antibody directed to the HER2 protein [29-31] has led to the design of trials studying the use of trastuzumab in the adjuvant setting. There are many prospective clinical studies that will investigate the possible role of trastuzumab in different combinations with cytotoxic drugs. There are many open questions: cardiotoxicity, confirmation Conclusion A large number of questions remains and some answers will hopefully appear over the next few years regarding the best use of adjuvant chemotherapy in breast cancer patients. These issues include the role of taxanes in the adjuvant therapy, the possible benefits of a dose-dense schedule of agents, the maturation of studies of high-dose chemotherapy and the determination of a possible benefit with the use of trastuzumab in the adjuvant setting. Future generations of clinical trials will highlight the need to optimize the integration of traditional breast cancer therapies with new-targeted strategies. Improved individualization of adjuvant therapy based on the identification of new and reliable predictive markers is our best hope for enhancing cure rates in the next decade. The treatment planning for all patients with breast cancer has to be multidisciplinary (Breast Care Unit) and has to offer participation in clinical trials to patients who are very well informed about their disease. Table 2. Phase III randomized adjuvant taxane breast cancer trials Study No. of patients Median follow-up Comparison 5-year DFS 5-year OS (months) (%) (%) CALGB 9344 [23] 3, AC x AC x 4 P x 4 70* 80* NSABP B 28 [26] 3, AC x AC x 4 P x 4 76* 85 BCIRG 001 [28] 1, TAC x 6 75* 87* FAC x CALGB 9741 [18] 2, Dose-dense arms II and IV Standard arms I and III 75* 90* DFS: disease-free survival; OS: overall survival; CALGB: Cancer and Leukemia Group B; AC: doxorubicin and cyclophosphamide; P: paclitaxel; NSABP: National Surgical Adjuvant Breast and Bowel Project; FAC: fluorouracil, doxorubicin, and cyclophosphamide; BCIRG: Breast Cancer International Research Group; TAC: docetaxel, doxorubicin, and cyclophosphamide *p <0.05; 82% (4-year DFS)
5 179 References 1. Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 1998; 352: Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node positive breast cancer: The results of 20 years of follow-up combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1995; 332: Lindeman GJ, Boyages J, Driessen C, Langlands AO. Intravenous or oral adjuvant CMF for node-positive breast cancer. Aust N Z J Surg 1992; 62: Engelsman E, Klijn JC, Rubens RD et al. «Classical» CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Cooperative Group Phase III Trial (10808). Eur J Cancer 1991; 27: Early Breast Cancer Trialists Collaborative Group: Analysis overview results. Fifth Meeting of the Early Breast Cancer Trialists Collaborative Group, Oxford, United Kingdom, September 21-23, Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in node positive breast cancer patients with tamoxifen non-responsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: Chambers SK, Chopyk RL, Chambers JT et al. Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer. Cancer 1989; 64: Lenaz I, Page JA. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 1976; 3: French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: Coombes RC, Bliss JM, Wils J et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 1996; 14: Poole CJ, Earl HM, Dunn A et al. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Proc Am Soc Clin Oncol 2003; 22: 4 (abstr 13). 14. Fisher B, Anderson S, Wicherham DL et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15: Fisher B, Anderson S, DeCillis A et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999; 17: Wood WC, Budman DR, Korzun AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: Citron M, Berry D, Cirrincione C et al. Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) vs. combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB 9741, INT C9741). Program / abstracts 25th Breast Cancer Symp; Dec 11-14, 2002; San Antonio, Texas (abstr 15). 18. Citron M, Berry D, Cirrincione C et al. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial J Clin Oncol 2003; 21: Hortobagyi GN, Buzdar A, Champlin R et al. Lack of efficacy of adjuvant high dose (HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC): a randomized trial. Proc Am Soc Clin Oncol 1998; 18: 2a (abstr 471). 20. Peters WP, Rosner G, Vredenburgh J et al. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 1999; 18: 1a (abstr 2). 21. The Scandinavian Breast Cancer Study Group Results from a randomized adjuvant breast cancer study with highdose chemotherapy with CTCb supported by autologous bone marrow stem cells vs dose-escalated and tailored FEC therapy. Proc Am Soc Clin Oncol 1999; 18:2a (abstr 3). 22. Rodenhuis S, Bontenbal M, Beex L et al. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. Proc Am Soc Clin Oncol 2000; 19:74a (abstr 286). 23. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: [Abstract/Free Full Text]. 24. Thomas E, Buzdar A, Theriault R et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of a prospective randomized clinical trial. Proc Am Soc Clin Oncol 2000; 19: 74a (abstr 285). 25. Eifel P, Axelson JA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1 3, J Natl Cancer Inst 2001;93: [Abstract/Free Full Text].
6 Mamounas EP, Bryant J, Lembersky BC et al. Paclitaxel (T) following doxorubicin/ cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc Am Soc Clin Oncol 2003; 22: 4 (abstr 12). 27. Nabholtz JM, Pienkowski T, Mackey J et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 0001 study. Proc Am Soc Clin Oncol 2002; 21 (abstr 141). 28. Martin M, Pienowski T, Mackey J et al. TAC improves disease-free survival and overall survival over FAC in node positive breast cancer patients, BCIRG 001: 55 months follow up. Breast Cancer Res Treat 2003; 82 (Suppl 1): (abstr 43). 29. Slamon D, Leyland-Jones B, Shak S et al. Addition of Herceptin TM (humanized anti-her2 antibody) to first line chemotherapy for HER2 overexpression of metastatic breast cancer (HER2 + MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998; 17 (abstr 377). 30. Cobleigh MA, Vogel CL, Tripathy D et al. Efficacy and safety of Herceptin TM (humanized anti-her2 antibody) as single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998; 17 (abstr 376). 31. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185her2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:
Breast cancer has the highest incidence among those
Medical Treatment of Breast Cancer Young Seon Hong, M.D. Department of Internal Medicine Catholic University of Korea, St. Mary's Hospital E mail : y331@cmc.cuk.ac.kr Abstract Breast cancer has the highest
More informationKey Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
More informationTreatment of HER-2 positive breast cancer
EJC SUPPLEMENTS 6 (2008) 21 25 available at www.sciencedirect.com journal homepage: www.ejconline.com Treatment of HER-2 positive breast cancer Matteo Clavarezza, Marco Venturini * Ospedale Sacro Cuore
More informationSequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide
Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide Review Article [1] April 01, 1997 By Clifford A. Hudis, MD [2] The recognition of paclitaxel's (Taxol's) activity
More informationChemotherapy of Breast Cancer
Japan - Taiwan Joint Symposium on Medical Oncology Session 7 Breast cancer journal homepage:www.cos.org.tw/web/index.asp Chemotherapy of Breast Cancer Mei-Ching Liu Department of Medicine, Koo Foundation
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More information30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER
EDUCATIONAL HIGHLIGHTS FROM DATA PRESENTED AT THE 30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER DECEMBER 13 16, 2007, SAN ANTONIO, TX, USA 2 CONTENTS
More informationAdjuvant treatment for early breast cancer
Annals of Oncology 16 (Supplement 2): ii182 ii187, 2005 doi:10.1093/annonc/mdi709 Adjuvant treatment for early breast cancer I. Smith The Royal Marsden Hospital, London, UK Introduction Survival rates
More informationRelative dose intensity delivered to patients with early breast cancer: Canadian experience
M E D I C A L O N C O L O G Y Relative dose intensity delivered to patients with early breast cancer: Canadian experience S. Raza MD, S. Welch MD, and J. Younus MD ABSTRACT Adjuvant chemotherapy for early
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More information新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方
新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方 文件修訂記錄 修正次數 修正日期 修正版別 修 改 內 容 1 2011.04.07 1.0 初次訂定 2 2013.05.08 2.0 修訂 3 2013.04.30 3.0 修訂 :Triple-Negative Breast Cancer 處方 新增 :Neoadjuvant-p7~8 4 2014.04.29 4.0 修訂 :FEC + Trastuzumab
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationClinical Expert Submission Template
Clinical Expert Submission Template Thank you for agreeing to give us a personal statement on your view of the technology and the way it should be used in the NHS. Health care professionals can provide
More informationAdjuvant Chemotherapy + Trastuzumab
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Chemotherapy + Trastuzumab (Optimal Drugs / Dosage / Trastuzumab) Adjuvant Chemotherapy (Optimal Drugs / Optimal Dosage
More informationReview Recent advances in systemic therapy Advances in adjuvant systemic chemotherapy of early breast cancer Sara López-Tarruella and Miguel Martín
Review Recent advances in systemic therapy Advances in adjuvant systemic chemotherapy of early breast cancer Sara López-Tarruella and Miguel Martín Medical Oncology Department, Clínico San Carlos Hospital,
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationToxicities of Chemotherapy Regimens used in Early Breast Cancer
Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline
More informationAnthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial
Anthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Dallas, TX Early Breast Cancer
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More informationThe absolute benefit from chemotherapy for both older and younger patients appeared most significant in ER-negative populations.
Hello, my name is Diane Hecht, and I am a Clinical Pharmacy Specialist at the University of Texas MD Anderson Cancer Center. It s my pleasure to talk to you today about the role of chemotherapy in this
More informationDose Intensity for Breast Cancer
Review Article [1] June 01, 2001 By Deborah K. Armstrong, MD [2] and Nancy E. Davidson, MD [3] Despite nearly 20 years of study, the importance of chemotherapy dose intensity in breast cancer remains unclear.
More informationRecent advances in adjuvant systemic treatment for breast cancer: all systems go!
REVIEW ARTICLE Recent advances in adjuvant systemic treatment for breast cancer: all systems go! P.N. Fishman MD* and S. Verma MD MSEd* KEY WORDS Breast cancer, adjuvant, treatment 1. INTRODUCTION Breast
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationCancer Care Ontario Practice Guidelines Initiative Sponsored By: Cancer Care Ontario & the Ministry of Health and Long-term Care
Cancer Care Ontario Practice Guidelines Initiative Sponsored By: Cancer Care Ontario & the Ministry of Health and Long-term Care Adjuvant Systemic Therapy for Node-negative Breast Cancer ORIGINAL GUIDELINE:
More informationAdjuvant Systemic Therapies in Breast Cancer
Adjuvant Systemic Therapies in Breast Cancer Leonel F. Hernandez-Aya, MD a, Ana M. Gonzalez-Angulo, MD, MSc b,c,d, * KEYWORDS Adjuvant Breast cancer Adjuvant endocrine Adjuvant chemotherapy Adjuvant HER-2-targeted
More informationTaxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1
Important data from BCIRG 006 Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 in the adjuvant treatment of HER2+ breast
More informationClinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationHerceptin (Trastuzumab): Adjuvant and Neoadjuvant Trials
Herceptin (Trastuzumab): Adjuvant and Neoadjuvant Trials Neora Yaal-Hahoshen MD and Tamar Safra MD Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Affiliated to Sackler Faculty
More informationSANDRA M. SWAIN. Washington Cancer Institute, Washington, District of Columbia, USA
The Oncologist Early-Stage Breast Cancer: Clinical Update Chemotherapy: Updates and New Perspectives SANDRA M. SWAIN Washington Cancer Institute, Washington, District of Columbia, USA Key Words. Breast
More informationAdjuvant systemic therapies in women with operable breast cancer: A daily medical practice in a single institution
Turkish Journal of Cancer Volume 35, No.3, 2005 123 Adjuvant systemic therapies in women with operable breast cancer: A daily medical practice in a single institution B NNAZ DEM RKAN 1, LKNUR B LKAY GÖRKEM
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationSymposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
Annals of Oncology 12 (Suppl. I): S57-S62, 2001. 2001 Kluwer Academic Publishers. Primed in the Netherlands. Symposium article Trastuzumab combined with chemotherapy for the treatment of HER2-positive
More informationSANDRA M. SWAIN. Washington Cancer Institute, Washington, District of Columbia, USA
The Oncologist Chemotherapy: Updates and New Perspectives SANDRA M. SWAIN Washington Cancer Institute, Washington, District of Columbia, USA Key Words. Breast cancer Chemotherapy Taxane Trastuzumab Ki-67
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cortazar P, Zhang L, Untch M, et al. Pathological
More informationPIO Treffen Berlin Mammacarcinom
PIO Treffen Berlin 2009 Mammacarcinom Qualitätssicherungsprojekt Adjuvante Chemotherapie T-Status 8% 92% T 1/2 T 3/4 Qualitätssicherungsprojekt Adjuvante Chemotherapie T-Status T-Stadien Therapie T 1/2
More informationADVANCES IN the adjuvant chemotherapy of primary,
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node- Positive Primary Breast Cancer: First
More informationNon-anthracycline Adjuvant regimens in Early Breast Cancer. Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center
Non-anthracycline Adjuvant regimens in Early Breast Cancer Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center Contents Role of Anthracyclines in adjuvant treatment EBCTCG2012
More informationBreast Cancer. Controversies in the Therapy of Early Stage Breast Cancer. The Oncologist 2005;10:
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Breast Cancer Controversies in the Therapy of Early Stage Breast
More informationIdeal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria
Ideal neo-adjuvant Chemotherapy in breast ca Dr Khanyile Department of Medical Oncology, University of Pretoria When is neo-adjuvant Chemo required? Locally advanced breast ca: - Breast conservative surgery
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationIncidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey
MEDICAL ONCOLOGY Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey S. Saibil MD PhD,* B. Fitzgerald
More informationExiste-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon
Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon In 25 results of 4 Adjuvant Herceptin trials have definitively
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationBristol-Myers Squibb Pharmaceuticals Ltd Taxol Early Breast Cancer SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE TAXOL (PACLITAXEL) FOR THE ADJUVANT TREATMENT OF EARLY BREAST CANCER Page 1 of 86 Background The purpose of the background section
More informationCopyright, 1995, by the Massachusetts Medical Society
Copyright, 99, by the Massachusetts Medical Society Volume 332 APRIL 6, 99 Number ADJUVANT CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE- POSITIVE BREAST CANCER The Results of Years of Follow-up
More informationVinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Original article Annals of Oncology 14: 699 703, 2003 DOI: 10.1093/annonc/mdg199 Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationIs adjuvant chemotherapy necessary for Luminal A-like breast cancer?
JBUON 2018; 23(4): 877-882 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?
More informationImpact of chemotherapy-induced amenorrhea on the prognosis of early breast cancer patients
Impact of chemotherapy-induced amenorrhea on the prognosis of early breast cancer patients Hanaa M.Kohel, MD 1 ; Yousri A.Rostom, MD 2 ; Osama H.El-Zaafarany, MD 3 ; Hazem F.Elaakad, MD 4 (1)Medical Research
More informationUse of Taxanes in Older Breast Cancer Patients
SIOG Guidelines Update 2014: Use of Taxanes in Older Breast Cancer Patients Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Fundamental steps Task Force (TF) on
More information亞東紀念醫院 Breast Cancer 化學治療處方集
亞東紀念醫院 Breast Cancer 化學治療處方集 2008-08 制定 最近修改日期 :2015-01 CMF Breast cancer 化學治療處方參考集 Adjuvant Classic CMF Cyclophosphamide 100mg/m2 PO qd; D1-D14 Methotrexate 40mg/m 2 in N/S 100 ml IV drip 30 mins; D1,
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationAdjuvant Chemotherapy TNBC & HER2 Subtype
Adjuvant Chemotherapy TNBC & HER2 Subtype 2015.08.15 Gun Min Kim Yonsei Cancer Center Division of Medical Oncology Department of Internal Medicine Yonsei University College of Medicine gmkim77@yuhs.ac
More informationThe Three Ages of Systemic Adjuvant Therapy for EBC
The Three Ages of Systemic Adjuvant Therapy for EBC 1896-2018 Nicholas Wilcken Westmead Hospital Petersham Institute University of Sydney Questions to be answered (concentrating on chemotherapy) Why should
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationTaxane/Anthracycline Combinations: Setting a New Standard in Breast Cancer?
Taxane/Anthracycline Combinations: Setting a New Standard in Breast Cancer? JEAN-MARC NABHOLTZ, ALESSANDRO RIVA University of California at Los Angeles, Jonsson Comprehensive Cancer Center at UCLA, Los
More informationDoes HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey
MYERS et al. ORIGINAL ARTICLE Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey J.A. Myers MD FRCPC, G.
More informationIntensifiedCT with stemcellrescue for high-riskprimary breastcancer
IntensifiedCT with stemcellrescue for high-riskprimary breastcancer Paolo PEDRAZZOLI SC Oncologia p.pedrazzoli@smatteo.pv.it Trend of HDC BC in Europe: 1992-2012: data from the EBMT registry Phase III
More informationreviews CMF revisited in the 21st century E. Munzone 1 *, G. Curigliano 1, H. J. Burstein 2, E. P. Winer 2 & A. Goldhirsch 1 introduction
Annals of Oncology 23: 305 311, 2012 doi:10.1093/annonc/mdr309 Published online 29 June 2011 CMF revisited in the 21st century E. Munzone 1 *, G. Curigliano 1, H. J. Burstein 2, E. P. Winer 2 & A. Goldhirsch
More informationHerceptin Pivotal Studies
Herceptin Pivotal Studies Nuhad K Ibrahim, MD, FACP Associate Professor of Medicine Breast Medical Oncology Department MD Anderson Cancer Center Houston, TX, USAE-mail: nibrahim@mdanderson.org Herceptin
More informationOncologist. The. Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience
The Oncologist Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience JOHN CROWN, MICHAEL O LEARY, WEI-SEONG OOI St. Vincent s University Hospital, Dublin, Ireland
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationComing of Age: Breast Cancer in Seniors HYMAN B. MUSS
The Oncologist Understanding and Treating Triple-Negative Breast Cancer Across the Age Spectrum Coming of Age: Breast Cancer in Seniors HYMAN B. MUSS The University of North Carolina Lineberger Cancer
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationPaclitaxel, Anthracycline, Gemcitabine & Cyclophosphamide. vs.
Version 6.0, November 2011 Protocol No.: BR3021 ISRCTN 51146252 EudraCT No.: 2004-002927-41 tango Paclitaxel, Anthracycline, Gemcitabine & Cyclophosphamide E C G T vs. E C G T A randomised phase III trial
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationoriginal articles introduction
Annals of Oncology 19. List HJ, Reiter R, Singh B et al. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 2001; 68: 21 28. 20. Jansson A, Delander
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationPaclitaxel in Breast Cancer
Paclitaxel in Breast Cancer EDITH A. PEREZ Mayo Foundation and Mayo Clinic Jacksonville, Jacksonville, Florida, USA Key Words. Paclitaxel Antineoplastic agents Breast neoplasms Clinical trials ABSTRACT
More informationAdjuvant chemotherapy for early-stage breast cancer patients daily clinical practice in selected cancer centres in Poland
Original article NOWOTWORY Journal of Oncology 2017, volume 67, number 2, 96 102 DOI: 10.5603/NJO.2017.0015 Polskie Towarzystwo Onkologiczne ISSN 0029 540X www.nowotwory.edu.pl Adjuvant chemotherapy for
More informationBreast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States.
Dr. Andrew Seidman s Commentary I. Breast Cancer Overview Breast cancer remains the most common malignancy and the second leading cause of cancer mortality in women in the United States. The following
More informationA population-based study on the patterns of use of different chemotherapy regimens in patients with early breast cancer
Published 11 April 2012, doi:10.4414/smw.2012.13571 Cite this as: A population-based study on the patterns of use of different chemotherapy regimens in patients with early breast cancer Markus Joerger
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationExtended Adjuvant Endocrine Therapy
Extended Adjuvant Endocrine Therapy After all, 5 years Tamoxifen works.. For women with ER+ primary breast cancer, previous studies have shown that treatment with tamoxifen for 5 years has a carry-over
More informationUpdate from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002
Update from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002 Nearly 5,000 physicians, oncologists, radiologists, epidemiologists, basic scientists, and breast cancer advocates from
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationAdjuvant Systemic Therapy for Node-negative Breast Cancer
Evidence-based Series 1-8 EDUCATION AND INFORMATION 2010 Adjuvant Systemic Therapy for Node-negative Breast Cancer Members of the Breast Cancer Disease Site Group A Quality Initiative of the Program in
More informationKEY WORDS Autologous transplantation High-dose chemotherapy Peripheral blood progenitor cells Bone marrow Neoadjuvant chemotherapy Breast neoplasm
Biology of Blood and Marrow Transplantation 10:794-804 (2004) 2004 American Society for Blood and Marrow Transplantation 1083-8791/04/1011-0007$30.00/0 doi:10.1016/j.bbmt.2004.07.009 The Use of High-Dose
More informationCASE STUDIES CLINICAL CASE SCENARIOS. Matthew J. Ellis, MD, PhD
CLINICAL CASE SCENARIOS Matthew J. Ellis, MD, PhD Clinicians face daily challenges in the management of individual patients with breast cancer who demonstrate different characteristics in terms of estrogen
More information乳癌化療指引. Breast Cancer
乳癌化療指引 103 年 12 月第五版 99-102 年, 第一至四版 注意事項 : 本院癌症團隊基於實證醫學制定此化學治療指引 : 本院癌症團隊基於實證醫學制定此化學治療指引, 實證醫學之結論源自臨床詴驗, 實證醫學之結論源自臨床詴驗, 惟參與臨床詴驗之研究對象多以 70 歲以下之病人為主, 故建議 70 歲以上病人接受治療時, 應依據病人實際臨床狀況進行抗癌藥物劑量之調整! 健保藥品給付限制註記說明
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationIntegration of Systemic Chemotherapy in the Management of Primary Breast Cancer
Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer FRANCISCO J. ESTEVA, GABRIEL N. HORTOBAGYI Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer
More informationEarly and locally advanced breast cancer: diagnosis and management
National Institute for Health and Care Excellence Final Early and locally advanced breast cancer: diagnosis and management [E] Evidence reviews for adjuvant chemotherapy NICE guideline NG101 Evidence reviews
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Dilemmas in Adjuvant Chemotherapy Is adjuvant chemotherapy effective in ER+
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More information